Veru's Enobosarm Shows Muscle In Wegovy Combo Trial
1. VERU reports favorable Phase 2b trial results for enobosarm with semaglutide. 2. No serious adverse events were observed, indicating strong safety profile for enobosarm. 3. Enobosarm improves fat loss and retains lean mass in older patients significantly. 4. Phase 3 program planned based on successful trial outcomes and results. 5. VERU stock price surged 22.5% following promising safety and efficacy data.